CD-138 Immunohistochemistry at Test Zone Diagnostic Center

CD-138 Immunohistochemistry at Test Zone Diagnostic Center

CD-138 Immunohistochemistry at Test Zone Diagnostic Center is a highly specialized, state-of-the-art pathological analysis used to identify and quantify plasma cells within tissue specimens. CD-138, also scientifically known as Syndecan-1, is a transmembrane heparan sulfate proteoglycan that is predominantly expressed on the surface of mature plasma cells and certain epithelial cells. In the realm of modern diagnostic pathology, immunohistochemistry (IHC) serves as an indispensable tool, utilizing highly specific antigen-antibody binding reactions to visualize cellular proteins that are otherwise invisible under standard light microscopy. By applying monoclonal antibodies targeted against the CD-138 antigen, pathologists at Test Zone Diagnostic Center in Lahore, Pakistan, can achieve unparalleled precision in diagnosing a wide array of reproductive, inflammatory, and hematological disorders.

The clinical importance of CD-138 Immunohistochemistry cannot be overstated. In gynecological pathology, it is recognized as the gold standard for diagnosing chronic endometritis, a silent inflammatory condition of the inner uterine lining that is strongly associated with unexplained infertility, recurrent pregnancy loss, and in vitro fertilization (IVF) implantation failures. Under routine Hematoxylin and Eosin (H&E) staining, plasma cells can easily be missed or confused with endometrial stromal cells, lymphocytes, or pre-decidualized stromal cells due to morphological similarities. CD-138 IHC eliminates this diagnostic ambiguity by producing a distinct, intense membranous brown stain on plasma cells, allowing for their rapid and accurate identification. Furthermore, in hematopathology, CD-138 IHC is vital for the evaluation of bone marrow biopsies to diagnose, stage, and monitor plasma cell proliferative disorders, including multiple myeloma and solitary plasmacytoma.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-138 Immunohistochemistry is performed on a tissue specimen that has already been obtained via a biopsy or surgical resection, patient preparation primarily relates to the specific biopsy procedure itself. If you are scheduled to undergo an endometrial biopsy or a bone marrow biopsy at Test Zone Diagnostic Center, please observe the following guidelines:

• Consultation and Medical History: Inform your physician about all current medications, especially blood thinners such as aspirin, clopidogrel, warfarin, or direct oral anticoagulants, which may need to be temporarily discontinued prior to the biopsy.
• Timing of the Biopsy: For endometrial biopsies, your gynecologist will determine the optimal timing during your menstrual cycle, which is typically during the luteal phase (days 19 to 24 of a standard cycle) to assess endometrial receptivity and chronic endometritis.
• Fasting Requirements: If your bone marrow biopsy or endometrial biopsy is to be performed under conscious sedation or general anesthesia, you will be instructed to fast (no food or liquids) for at least 6 to 8 hours before the procedure.
• Pain Management: Your physician may recommend taking a mild over-the-counter pain reliever, such as ibuprofen, approximately one hour before an endometrial biopsy to minimize uterine cramping.
• Submission of Existing Blocks: If you are submitting a pre-existing formalin-fixed, paraffin-embedded (FFPE) tissue block or slides from another facility for a second opinion or specialized IHC staining, no physical preparation is required. Simply present the tissue block along with the original histopathology report and referral letter to our reception desk.

During the Procedure

The diagnostic journey of CD-138 Immunohistochemistry involves a highly controlled laboratory sequence executed by skilled histotechnologists and evaluated by consultant pathologists at Test Zone Diagnostic Center:

• Specimen Collection: The relevant tissue (such as an endometrial pipelle biopsy, bone marrow trephine biopsy, or surgical specimen) is collected by your clinical specialist using sterile, minimally invasive techniques.
• Tissue Fixation: Immediately after collection, the tissue is placed in a vial containing 10% neutral buffered formalin. This critical step preserves the cellular architecture and prevents autolysis, ensuring that the CD-138 antigens remain stable.
• Processing and Embedding: In our pathology laboratory, the tissue undergoes dehydration and clearing before being embedded in high-grade paraffin wax to form a solid block.
• Microtomy: Ultra-thin sections, measuring approximately 3 to 4 micrometers, are cut from the paraffin block using a precision microtome and mounted onto positively charged glass slides.
• Antigen Retrieval: To reverse the protein cross-linking caused by formalin fixation, the slides undergo Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions, exposing the CD-138 epitopes for antibody binding.
• Antibody Incubation: The slides are incubated with primary monoclonal antibodies directed against CD-138. This is followed by the application of a secondary detection system conjugated with horseradish peroxidase (HRP) and a chromogen substrate (typically diaminobenzidine, or DAB), which produces a visible brown precipitate on the cell membranes of CD-138 positive cells.
• Microscopic Evaluation: The stained slides are counterstained with hematoxylin to visualize cell nuclei, dehydrated, coverslipped, and meticulously analyzed under a high-power light microscope by our consultant pathologist.

When is a CD-138 Immunohistochemistry Performed?

Investigation of Unexplained Infertility and Recurrent Implantation Failure

Reproductive endocrinologists frequently request CD-138 Immunohistochemistry for patients experiencing unexplained infertility or recurrent implantation failure (RIF) during assisted reproductive technology (ART) cycles. Chronic endometritis is often asymptomatic or presents with non-specific symptoms, yet it significantly impairs endometrial receptivity. By identifying the presence of endometrial stromal plasma cells via CD-138 IHC, clinicians can diagnose this inflammatory state and initiate targeted antibiotic therapy to restore the uterine environment, thereby improving subsequent pregnancy rates.

Evaluation of Recurrent Pregnancy Loss

Recurrent pregnancy loss (RPL) is a deeply challenging clinical condition defined by consecutive pregnancy losses. Chronic endometritis, characterized by persistent mucosal inflammation, is a recognized and treatable cause of RPL. The localized inflammatory response alters the normal cytokine profile and immune cell distribution within the endometrium, disrupting early placentation. Performing CD-138 IHC on an endometrial biopsy allows pathologists to detect low-grade chronic inflammation, enabling timely intervention to support future successful gestations.

Diagnosis and Monitoring of Multiple Myeloma

In hematological oncology, CD-138 Immunohistochemistry is a cornerstone for diagnosing multiple myeloma, a malignant neoplasm of plasma cells. When a patient presents with symptoms such as bone pain, pathological fractures, unexplained anemia, renal impairment, or hypercalcemia, a bone marrow biopsy is performed. CD-138 IHC allows the pathologist to clearly distinguish malignant plasma cells from other marrow elements, accurately estimate the percentage of plasma cell infiltration, and monitor the patient’s response to chemotherapy or stem cell transplantation.

Identification of Solitary Plasmacytoma

A solitary plasmacytoma is a localized accumulation of neoplastic plasma cells that can occur either within the bone (solitary bone plasmacytoma) or in soft tissues (extramedullary plasmacytoma). Because these tumors can mimic other poorly differentiated malignancies or lymphomas, CD-138 IHC is utilized to confirm the plasma cell lineage of the tumor cells, facilitating an accurate diagnosis and preventing inappropriate therapeutic interventions.

Differentiating Complex Lymphoproliferative Disorders

Pathologists frequently encounter diagnostic challenges when evaluating lymph node or tissue biopsies with dense lymphoid infiltrates. CD-138 Immunohistochemistry is employed alongside a comprehensive panel of other IHC markers (such as CD20, CD3, CD19, Kappa, and Lambda light chains) to differentiate between reactive plasma cell hyperplasia, plasmablastic lymphoma, primary effusion lymphoma, and other B-cell lymphoproliferative disorders, ensuring a precise and reliable diagnosis.

What Does a CD-138 Immunohistochemistry Detect?

CD-138 Immunohistochemistry is designed to detect, localize, and quantify specific cellular features within tissue sections. The test detects and evaluates:

• The presence of endometrial stromal plasma cells, which is the diagnostic hallmark of chronic endometritis.
• The spatial distribution of plasma cells within the endometrial tissue (focal, diffuse, or clustered).
• The exact number of plasma cells per high-power field (HPF) to determine the severity of endometrial inflammation.
• The percentage of plasma cell infiltration in bone marrow trephine biopsies for staging multiple myeloma.
• The presence of clonal or neoplastic plasma cell populations in suspected plasmacytoma lesions.
• The expression of CD-138 on the cell membranes of epithelial cells, assisting in the evaluation of epithelial integrity.
• The loss of CD-138 expression in certain carcinomas, which can correlate with epithelial-mesenchymal transition (EMT) and tumor aggressiveness.
• The presence of plasma cells in chronic inflammatory lesions of the gastrointestinal tract, such as inflammatory bowel disease (IBD).
• The infiltration of plasma cells in chronic salivary gland disorders, aiding in the evaluation of autoimmune conditions like Sjögren’s syndrome.
• The presence of CD-138 positive cells in chronic osteomyelitis specimens to confirm chronic bone infection.
• The differentiation of plasmablastic lymphoma from other high-grade B-cell lymphomas.
• The identification of plasma cells in chronic inflammatory dermatoses.
• The presence of plasma cells in chronic cholecystitis and other chronic visceral inflammatory conditions.
• The detection of minimal residual disease (MRD) in post-treatment bone marrow biopsies for plasma cell dyscrasias.
• The confirmation of plasma cell infiltration in autoimmune hepatitis biopsies.
• The presence of plasma cells in chronic middle ear infections (chronic otitis media) tissue specimens.
• The evaluation of plasma cell populations in transplant rejection biopsies, where plasma cell-rich infiltrates may indicate specific rejection pathways.
• The presence of CD-138 positive cells in deciduoid variants of mesothelioma.
• The characterization of primary effusion lymphoma cells, which typically express CD-138.
• The exclusion of plasma cell involvement in reactive lymphoid hyperplasia.
• The presence of plasma cells in chronic cervicitis specimens.
• The identification of plasma cells in chronic periapical granulomas in oral pathology.
• The distribution of plasma cells in chronic thyroiditis (Hashimoto’s thyroiditis) tissue.
• The presence of plasma cells in chronic pancreatitis specimens.
• The expression of CD-138 in specific pediatric small round blue cell tumors to rule out diagnostic mimics.
• The presence of plasma cells in chronic vascular inflammatory conditions.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that waiting for pathology results can be an anxious time for patients and their families. Immunohistochemistry is a highly complex, multi-step process that requires meticulous laboratory preparation, precise staining controls, and expert microscopic analysis by our consultant pathologists. Typically, the turnaround time for CD-138 Immunohistochemistry is between 3 to 5 working days from the time the tissue specimen or paraffin block is received at our laboratory. This timeframe ensures that all quality control measures are fully met and that every slide is thoroughly reviewed. Once the report is finalized, patients and their referring physicians can instantly access and download the digital report through the secure online portal of Test Zone Diagnostic Center, or collect a high-quality printed report from our main center in Lahore.

CD-138 Immunohistochemistry Findings Overview

The interpretation of CD-138 Immunohistochemistry depends heavily on the clinical context and the specific organ or tissue being evaluated. The table below outlines common parameters, normal findings, and potential abnormal findings associated with this test:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Endometrial Stroma (Infertility/RIF Workup)	Zero (0) CD-138 positive plasma cells per high-power field (HPF).	Presence of 1 or more CD-138 positive plasma cells in the stroma, confirming Chronic Endometritis.
Bone Marrow Trephine Biopsy	Scattered, polyclonal plasma cells representing less than 2-3% of total nucleated cells.	Sheet-like or clustered CD-138 positive plasma cells exceeding 10% (Multiple Myeloma) or 60% (active myeloma).
Soft Tissue / Bone Lesion	No abnormal aggregates of plasma cells.	Dense, monoclonal sheets of CD-138 positive plasma cells, diagnostic of Solitary Plasmacytoma.
Lymph Node Biopsy	Normal follicular architecture with rare, scattered plasma cells in the medullary cords.	Extensive CD-138 positive plasma cell infiltration or plasmablastic lymphoma.
Epithelial Tissues (e.g., skin, mucosa)	Strong, uniform membranous CD-138 expression in epithelial layers.	Reduced or completely lost CD-138 expression, often associated with invasive carcinomas or epithelial-mesenchymal transition.
Gastrointestinal Mucosa	Normal baseline population of polyclonal plasma cells in the lamina propria.	Markedly increased or depleted plasma cell populations, indicating chronic inflammatory bowel conditions.
Post-Treatment Bone Marrow	Complete absence of clonal plasma cells (Minimal Residual Disease negative).	Persistent, detectable CD-138 positive clonal plasma cells (Minimal Residual Disease positive).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for CD-138 Immunohistochemistry?

• Experienced healthcare professionals: Our pathology department is led by highly qualified consultant pathologists with extensive expertise in histopathology and specialized immunohistochemical diagnostics.
• Patient-focused care: We prioritize patient comfort, dignity, and clear communication at every stage of the diagnostic journey.
• Quality diagnostic services: Test Zone Diagnostic Center utilizes standardized, internationally recognized staining protocols and high-affinity antibodies to ensure maximum diagnostic sensitivity and specificity.
• Professional reporting: Our diagnostic reports provide detailed quantitative and qualitative assessments of CD-138 expression, offering clear guidance to your treating physician.
• Modern diagnostic approach: We utilize advanced, automated immunohistochemistry platforms that minimize human error and ensure highly reproducible staining results.
• Comfortable environment: Our state-of-the-art facility in Lahore, Pakistan, is designed to provide a welcoming, clean, and stress-free experience for all patients.
• Convenient location: Situated in a highly accessible area of Lahore, our center is easy to reach for patients from all parts of the city and surrounding regions.
• Commitment to accurate diagnosis: We understand the critical role our reports play in fertility treatments and oncology care, and we are dedicated to delivering the highest standards of diagnostic accuracy.